Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Measures to support a safer drug supply

Andrea Ryan, Andrea Sereda and Nadia Fairbairn
CMAJ December 07, 2020 192 (49) E1731; DOI: https://doi.org/10.1503/cmaj.77303
Andrea Ryan
International Collaborative Addiction Medicine research fellow and addiction medicine physician, BC Centre on Substance Use, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Sereda
Family physician, London Intercommunity Health Centre, London, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia Fairbairn
Assistant professor, Department of Medicine, University of British Columbia, Vancouver, BC
MD MHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Tyndall’s CMAJ commentary regarding safer supply, namely pharmaceutical alternatives to the poisoned drug supply fueling the overdose crisis, describes the roots of the overdose crisis and calls for a clear strategy to scale up safer supply prescribing.1 Addressing barriers to prescribing, coupled with the decriminalization of drugs, is essential to the success of this approach.

Tyndall discusses how the provision of safer supply by physicians has been met with reluctance, and that prescribing rates are too low to positively affect the overdose crisis.1 This is partly because of prescription review programs by regulatory colleges, with perceived inappropriate prescribing being grounds for reprimand. Federal Minister of Health Patty Hajdu released a letter calling on colleges to support clinicians and increase access to safer supply.2 As the minister points out, important measures to prevent opioid overprescribing must be weighed against the need to prescribe pharmaceutical alternatives. Supporting clinicians to prescribe without fear of reprisal may affect access to safer supply.

Prescribing rates, however, even for evidence-based therapies for opioid use disorder, are low among physicians, indicating that the widespread adoption of safer supply prescribing will be a challenge.3 A practitioner-led model requires engagement from more clinicians, with access to a wider array of opioid formulations, such as liquid hydromorphone and diacetylmorphine. Recently, British Columbia implemented a public health order that expanded prescribing of controlled substances by registered nurses.4 This is a major step for increasing access to safer supply.

In Ontario, safer supply programs have been in place for up to 5 years, showing preliminary results of decreased rates of overdose and infection, improvements in chronic disease management and decreases in illegal activities to fund illicit drug purchase.5 These programs are creating compelling evidence that many of the harms of illicit drug use are in fact related to the prohibition of these substances and our societal response to their use.5 Prime Minister Justin Trudeau specifically stated that the decriminalization of drugs is not being considered and that safer supply is the government’s key priority for addressing the overdose crisis.6 However, criminalizing drugs and the people who use them disproportionately affects poor and racialized groups, thereby undermining efforts made to improve access to health care services, including safer supply. Government officials should look to decriminalization as part of a plan to support expanded access to safer supply. This would require legislative change and coordination among government agencies, as has been done in response to coronavirus disease 2019 (COVID-19).

Swift and decisive action has been crucial to Canada’s success in limiting the spread of COVID-19. The same emphatic response is needed now to combat the overdose crisis. As we await a large-scale public health model of safe supply, clinicians must be supported by regulatory colleges to prescribe safer opioid alternatives in tandem with the decriminalization of drugs and the people who use them.

Footnotes

  • Competing interests: None declared.

References

  1. ↵
    1. Tyndall M
    . A safer drug supply: a pragmatic and ethical response to the overdose crisis. CMAJ 2020;192:E986–7.
    OpenUrlFREE Full Text
  2. ↵
    1. Hajdu P
    . Letter from the Minister of Health regarding treatment and safer supply. Ottawa: Government of Canada; 2020 Aug. 24.
  3. ↵
    1. Guan Q,
    2. Khuu W,
    3. Spithoff S,
    4. et al
    . Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. Drug Alcohol Depend 2017;177:315–21.
    OpenUrl
  4. ↵
    British Columbia Ministry of Health, Office of the Provincial Health Officer. Registered nurse and registered psychiatric nurse public health pharmacotherapy. Provincial health officer’s order. Available: www2.gov.bc.ca/assets/gov/health/about-bc-s-health-care-system/office-of-the-provincial-health-officer/covid-19/covid-pho-order-rn-pharmacotherapy.pdf (accessed 2020 Sept. 23).
  5. ↵
    1. Bonn M,
    2. Felicella G,
    3. Johnson C,
    4. et al
    . COVID-19, substance use, and safer supply: clinical guidance to reduce risk of infection and overdose [webinar]. Vancouver: British Columbia Centre on Substance Use; 2020.
  6. ↵
    1. Woo A
    . Trudeau says focus is on safe supply, not decriminalization as overdose deaths spike. The Globe and Mail [Toronto]. Available: www.theglobeandmail.com/canada/british-columbia/article-trudeau-says-focus-is-on-safe-supply-not-decriminalization-as/ (accessed 2020 Sept. 2).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (49)
CMAJ
Vol. 192, Issue 49
7 Dec 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Measures to support a safer drug supply
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Measures to support a safer drug supply
Andrea Ryan, Andrea Sereda, Nadia Fairbairn
CMAJ Dec 2020, 192 (49) E1731; DOI: 10.1503/cmaj.77303

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Measures to support a safer drug supply
Andrea Ryan, Andrea Sereda, Nadia Fairbairn
CMAJ Dec 2020, 192 (49) E1731; DOI: 10.1503/cmaj.77303
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • A safer drug supply: a pragmatic and ethical response to the overdose crisis
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire